Clinical Trial Update: Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating retreatment of chronic hepatitis C non-responders with pegylated interferon alfa-2a plus ribavirin and pioglitazone has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Actos (Pioglitazone)
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: University Hospital, Geneva | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED